U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07937748) titled 'Filsuvez in Infants With Dystrophic or Junctional Epidermolysis Bullosa' on Nov. 09.
Brief Summary: This pilot study will evaluate the safety and tolerability of Filsuvez, a topical gel, in newborns and infants younger than 6 months with dystrophic or junctional epidermolysis bullosa. Filsuvez is approved for patients 6 months of age and older but has not been studied in this younger population. Participants will receive Filsuvez for 180 days and will be followed with clinical assessments, laboratory testing, caregiver questionnaires, telephone contacts, and standardized photographs. The study will also explore changes in wound size...